Evidence map›Paper›PMID 35003325›Full record

ArticleComputational and mathematical methods in medicine2021

Network Pharmacology-Based Study on the Active Component and Mechanism of the Anti-Non-Invasive and Invasive Bladder Urothelial Carcinoma Effects of Zhuling Jisheng Decoction.

Chenyu Ma, Jianlong Wang, Na Zhao, Zhenya Pan, Yi Lu, Miao Cheng, Min Deng

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Computational and mathematical methods in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Chenyu MaThird People's Hospital, Ningbo City, Zhejiang Province, No. 51-139, Zhouxi Highway, Cixi, China.
Jianlong WangXi'an International Medical Center Hospital, China.
Na ZhaoEmergency Medicine Department, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, China.
Zhenya PanEmergency Medicine Department, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, China.
Yi LuYiwu Fuyuan Private Hospital, China.
Miao ChengDepartment of Oncology, The Third People's Hospital of Hangzhou, Hangzhou, Zhejiang, China.
Min DengEmergency Medicine Department, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, China.ORCID https://orcid.org/0000-0002-6945-7389
Zhejiang Hospital · CNThird People's Hospital of Hangzhou · CNWuxi Third People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zhuling Jisheng decoction is employed for the treatment of bladder urothelial cancer in clinical practice of traditional Chinese medicine. However, there are few studies on its precise mechanism. For the antibladder cancer action of Zhuling Jisheng decoction, a network pharmacological technique was used to design a component/target/pathway molecular regulatory network. The TCMSP dataset was used to identify the chemical makeup of Zhuling Jisheng decoction, which was then analyzed and assessed for oral bioavailability and pharmacological similarity. The chemical composition of Zhuling Jisheng decoction was identified through the TCMSP database, and it was evaluated and screened based on oral bioavailability and drug similarity. The GEO database was searched for genes associated with urothelial bladder carcinoma, and gene targets associated with bladder urothelial cancer resistance were chosen by comparison. The function and linked pathways of the target genes were examined and screened using annotation, visualization, and a comprehensive discovery database. The impact of Zhuling Jisheng decoction on urothelial bladder cancer was studied using Cytoscape software to create a component/target/pathway network. Finally, 69 and 55 target genes were discovered for noninvasive bladder urothelial cancer and invasive bladder urothelial cancer, respectively. In noninvasive urothelial cancer, 118 pathways were highly enriched, including the TNF signaling pathway and the IL-17 signaling route. 103 pathways were highly enriched in invasive urothelial cancer, including the p53 signaling route, bladder cancer route, and calcium signaling route. There were 18 and 15 drug targets associated with noninvasive and invasive bladder urothelial carcinoma prognoses. Many signaling pathways directly act on tumours, and indirect pathways inhibit the development of bladder urothelial carcinoma. This research establishes a scientific foundation for further research into the framework of action of Zhuling Jisheng decoction in the therapy of bladder urothelial cancer.

Indexed as

Antineoplastic Agents, PhytogenicApoptosisCell ProliferationCellular SenescenceComputational BiologyDrugs, Chinese HerbalGene Regulatory NetworksGenetic MarkersHumansInflammationMedicine, Chinese TraditionalNeovascularization, PathologicNetwork PharmacologyPlants, MedicinalPrognosisProtein Interaction MapsAntineoplastic Agents, PhytogenicDrugs, Chinese HerbalGenetic Markers

Identifiers

PMID35003325
PMCPMC8741376
OpenAlexW4206515221

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.